Analysis of adaptive response to bleomycin and mitomycin C

Area of Science:

• Molecular Biology
• Genetics
• Toxicology

Background:

• Cancer cells are characterized by genetic instability stemming from impaired DNA-repair mechanisms.
• Adaptive response (AR) is a phenomenon where cells develop resistance to genotoxic agents after exposure to low, non-genotoxic doses.
• AR is thought to involve enhanced DNA-repair systems or free radical detoxification.

Purpose of the Study:

• To investigate differences in AR induced by bleomycin (BLM) and mitomycin C (MMC), which cause DNA damage via distinct pathways.
• To evaluate the effectiveness of DNA-repair systems by analyzing AR in human lymphocytes.

Main Methods:

• The study utilized whole blood human lymphocytes to assess AR.
• Cytogenetic endpoints, chromosomal aberrations (CA) for BLM and sister chromatid exchanges (SCE) for MMC, were used to measure chromosomal instability.
• Cells were pre-treated with low doses of BLM or MMC before exposure to a challenging dose.

Main Results:

• A significant difference in protective effects was observed between BLM and MMC.
• Pre-treatment with low-dose BLM reduced CA frequency by nearly 50%, while MMC showed less than 20% protection.
• Individual variability in AR suggests differences in DNA-repair capacity among donors.

Conclusions:

• BLM induces a higher adaptive response compared to MMC in human lymphocytes.
• The greater AR by BLM may be linked to its specific DNA-damage repair processing.
• Individual variations in AR highlight the importance of personalized DNA-repair capacity assessment.